Sanofi's iGlarLixi: Two Formulations Raise FDA Red Flag On Dosing Errors

Sponsor's plan to market two self-injectable pens with different fixed-ratio concentrations of insulin glargine and lixisenatide may result in patients getting inappropriate dose, FDA says in advisory committee briefing documents that also question clinical utility.